{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'treatment, including 4 years post last treatment with', 'alemtuzumab.', 'Note: EOS refers to the end of the safety monitoring phase.', 'STUDY POPULATION', 'Inclusion criteria:', 'Main selection criteria', 'Patients with RRMS aged from 10 years (12 years in the', 'Russian Federation) to less than 18 years at study entry are', 'eligible. Patients must meet the criteria of diagnosis of MS as', 'defined by the International Paediatric Multiple Sclerosis', 'Study Group criteria for paediatric MS, and the criteria of MS', 'based on McDonald criteria 2010.', 'Signed written informed consent/assent obtained from patient', \"and patient's legal representative (parent or guardian)\", 'according to local regulations.', 'Expanded Disability Status Scale (EDSS) score 0.0 to 5.0', '(inclusive) at screening.', 'At least 2 recorded MS attacks, and at least 1 MS attack', '(relapse) in the last year during treatment with a IFNB or GA', 'after having been on that therapy for at least 6 months, and is', 'currently still taking the same therapy.', 'At least 1 of the following:', '-', '1 new or enlarging T2 hyperintense lesion or', 'gadolinium enhancing lesion while on that same prior', 'therapy (IFNB or GA), OR', '-', '2 or more relapses in the prior year, OR', '-', 'tried at least 2 MS DMTs.', 'Main exclusion criteria:', 'Any prior exposure to alemtuzumab.', 'Any progressive or nonrelapsing form of MS.', 'Treatment with natalizumab, daclizumab, fingolimod,', 'methotrexate, azathioprine, cyclosporine, or mycophenolate', 'mofetil in the last 6 months, or as determined by the treating', 'physician to have residual immune suppression from these or', 'other MS treatments.', 'Treatment with teriflunomide in the last 12 months except if', 'the patient underwent the accelerated elimination procedure', 'as per local teriflunomide label. Previous treatment with', 'mitoxantrone, cyclophosphamide, cladribine, rituximab,', 'ocrelizumab, leflunomide or any cytotoxic therapy.', 'CD4+, CD8+, or CD19+ absolute cell count in blood at', 'screening below lower limit of normal (LLN).', 'Prior documented history of thrombocytopenia, or platelet', 'count at screening <LLN. In case of borderline results, one', 'retest is allowed.', 'NOTE: Prior to initiation of any alemtuzumab treatment', 'course, contraindications should be reviewed as pre-', 'treatment verification of eligibility.', 'Total expected number of patients', 'At least 50 evaluable patients', 'Expected number of sites:', 'Approximately 50 sites', 'Property of the Sanofi Group - strictly confidential', 'Page 6', 'VV-CLIN-02544065.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'STUDY TREATMENT', 'Investigational medicinal product', 'Alemtuzumab', 'Formulation:', 'Concentrate for solution for infusion (sterile concentrate). Each', 'single-use vial contains 12 mg alemtuzumab (10 mg/mL; total', 'extractable volume 1.2 mL).', 'Route(s) of administration:', 'Intravenous (IV) infusion in a supervised medical setting', 'Dose regimen:', 'Alemtuzumab administered as daily IV infusion for 5 consecutive days', 'at Month 0 and for 3 consecutive days at Month 12. Calculation of the', 'dose used will be determined based on patient weight:', 'For patients >50 kg: 12 mg/day.', 'For patients <50 kg: 0.24 mg/kg/day (this equates to', '12 mg/day for a 50 kg patient).', 'Non Investigational medicinal product(s)', 'Premedications:', 'Day -1 (day before first IV infusion at each course) in the', 'Formulation:', 'morning:', '-', 'Oral prednisone/prednisolone,1 mg/kg or 50 mg one', 'dose, whichever is lower or equivalent,', '-', 'H2 antagonist according to the local label (eg, ranitidine).', 'Day -1 (day before first IV infusion at each course) in the', 'evening:', '-', 'H1 antagonist according to the local label (eg, cetirizine),', '-', 'H2 antagonist according to the local label (eg, ranitidine).', 'On days of IV infusions (1 hour prior to infusion):', '-', 'H2 antagonist: leg, ranitidine or equivalent,', '-', 'NSAID/antipyretic: Paracetamol or equivalent,', '-', 'H1 antagonist IV diphenhydramine (25 mg or appropriate', 'weight based dosing based on local health authority', 'recommendation), immediately followed by:', '-', 'IV methylprednisolone: administer 30 mg/kg or 1000 mg', '(whichever is lower) on infusion Days 1, 2, 3 (all', 'courses) and >500 mg on infusion Days 4 and 5 (if 5', 'days of infusion).', 'Notes:', 'a)', 'If diphenhydramine IV is not available, an equivalent H1', 'antagonist can be used at an equivalent dosing, via', 'IV route.', 'b)', 'If no H1 antagonist is available in IV formulation, an oral', 'formulation of an equivalent compound can be used at', 'an equivalent dosing, 2 hours prior to infusion.', 'Day 4 and Day 5 of the first course:', '-', 'H1 antagonist, H2 antagonist, and antipyretics as', 'needed,', '-', 'Fluid intake will be encouraged.', 'Concomitant medications:', 'Acyclovir 200 mg oral twice daily (or therapeutic equivalent)', 'will also be provided at the beginning on the first day of each', 'Property of the Sanofi Group - strictly confidential', 'Page 7', 'VV-CLIN-02544065 5.0']\n\n###\n\n", "completion": "END"}